Sanofi (OTCMKTS:SNYNF – Get Free Report) was the target of a large decline in short interest in February. As of February 28th ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Sanofi (EPA:SAN – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of €99.23 ($107.86) and traded as high ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...